The results are consistent with previous findings that cisplatin resistance decreased in ACC cells after inhibition of the NF-kB pathway, while activation of the NF-kB pathway promoted cisplatin resistance (Figure 6C). This evidence concerns the gene NFKB1 and adrenal cortex carcinoma.